SARAH WHITTLE to Neuroblastoma
This is a "connection" page, showing publications SARAH WHITTLE has written about Neuroblastoma.
Connection Strength
2.656
-
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417.
Score: 0.459
-
Blood product administration during high risk neuroblastoma therapy. Pediatr Hematol Oncol. 2020 Feb; 37(1):5-14.
Score: 0.439
-
Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma. Pediatr Hematol Oncol. 2017 Aug; 34(5):331-342.
Score: 0.382
-
Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017 Apr; 17(4):369-386.
Score: 0.363
-
The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma. Invest New Drugs. 2016 12; 34(6):685-692.
Score: 0.350
-
A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation. J Pediatr Hematol Oncol. 2016 Mar; 38(2):131-8.
Score: 0.338
-
Factors Impacting Time to Engraftment in Patients With High-risk Neuroblastoma Following Autologous Stem Cell Transplant. J Pediatr Hematol Oncol. 2020 10; 42(7):e569-e574.
Score: 0.116
-
Severe COVID-19 infection in a child receiving immunotherapy for cancer. Pediatr Blood Cancer. 2021 03; 68(3):e28710.
Score: 0.116
-
Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma. J Pediatr Hematol Oncol. 2017 11; 39(8):e486-e488.
Score: 0.095